IRC
ADCT icon

Investors Research Corp’s ADC Therapeutics ADCT Stock Holding History

Investors Research Corp’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20
Closed -$77 – 1126
2022
Q4 		$77 Hold
20
– – ﹤0.01% 1119
2022
Q3 		$0 Hold
20
– – ﹤0.01% 1080
2022
Q2 		$0 Hold
20
– – ﹤0.01% 1076
2022
Q1 		$0 Hold
20
– – ﹤0.01% 1019
2021
Q4 		$0 Hold
20
– – ﹤0.01% 980
2021
Q3 		$1K Hold
20
– – ﹤0.01% 935
2021
Q2 		$0 Hold
20
– – ﹤0.01% 972
2021
Q1 		$0 Buy
+20
New +$579 ﹤0.01% 969

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Investors Research Corp's ADCT Position: Q1 2023 in Review

Investors Research Corp sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 20 shares — an estimated $77 sold.

Investors Research Corp first reported a position in ADCT in Q1 2021 and held it in 8 quarters. The position peaked at $1K in Q3 2021. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

  • Investors Research Corp reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Investors Research Corp sold 20 ADC Therapeutics shares in Q1 2023, an estimated $77.
  • Investors Research Corp first reported a position in ADC Therapeutics in Q1 2021 and held it in 8 quarters.
  • Investors Research Corp's ADC Therapeutics position peaked at $1K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on Investors Research Corp's 13F filing for Q1 2023, filed 11 May 2023.